Compare Johnson Controls International PLC (JCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Neurocrine Biosciences Inc — how do they compare? Johnson Controls International PLC trades at $140 (market cap $85.03B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Johnson Controls International PLC is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Johnson Controls International PLC pays a 1.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JCI | NBIX | |
|---|---|---|
Market Cap | $85.03B | $17.40B |
Sector | Industrials | Health |
52-Week High | $148.21 | $180.55 |
52-Week Low | $103.24 | $123.10 |
Enterprise Value | $93.86B | $16.49B |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $141.71, up 0.89% with a bearish technical signal but strong analyst support. Recent earnings beats and a 14.45% net margin highlight operational strength, while valuation metrics like a P/E of 42.62 suggest premium pricing. The company maintains a dividend and benefits from positive news flow, including industry awards and strategic appointments.
Outlook is mixed: bullish fundamentals and analyst consensus target of $158.29 offer upside, but technical weakness and high valuation pose risks. Key drivers include execution in building systems and data center demand, while debt levels and economic sensitivity require monitoring for sustained growth.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
